Rev Invest Clin. 2009 May-Jun;61(3):252-66. Spanish.
Guidelines in RA treatment: concepts on safety and recommendations using anti-TNF-alpha inhibitors Díaz-Jouanen E, Abud-Mendoza C, Garza-Elizondo MA, Medrano-Ramírez G, Burgos-Vargas R, Orozco-Alcalá JJ, Pacheco-Tena CF, Pineda C, Pozos-Espíndola JC, Ramos-Niembro F, Robles-San-Román M, Santana-Sahagún JE. Facultad de Medicina Universidad Nacional Autónoma de México, Hospital Angeles Lomas. diazj@iname.com Recommendations for the use of Disease-Modifying Antirheumatic Drugs (DMARD) with both conventional and biological agents in Rheumatoid Arthritis (RA) must be based on their safety profile, adverse effects, risks, and advantages. With the purpose of presenting the most updated information about the safety of tumor necrosis factor alpha (TNFalpha) antagonists, in this article we summarize the literature published during the last three years about this sort of biological agents in specific clinical situations, such as risk of developing infections, cancer, cardiovascular diseases, and autoimmunity; as well as their administration to patients who will undergo surgical procedures, pregnant and/or breast-feeding women, and patients who need immunizations. Likewise, in this analysis we offer specific recommendations, based on evidence, for the best anti-TNF-alfa management.